Shares of Erasca fell over 45% in premarket trading on April 28, 2026, after the company disclosed that it received a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 infringes a Revolution patent and is connected to alleged trade secret misappropriation. The disclosure came the same day Erasca announced preliminary Phase 1 dose-escalation data for ERAS-0015.
Contact our attorneys for a no-cost case evaluation.